| 41. |
- H., Olsson, et al.
(författare)
-
Worse breast cancer prognosis in insulin treated diabetic patients - A population based registry study in Sweden
- 2015
-
Ingår i: Cancer Research. - 0008-5472. ; 75:9 Suppl
-
Konferensbidrag (refereegranskat)abstract
- Background. Diabetes may be linked to incidence of different tumor diseases and prognosis through various mechanisms such as the disease itself, hyperglycemia, obesity and anti-diabetes therapy. Material and methods. The study includes all women with BC diagnosed in Sweden between 2000 through 2008 (n=54406). The women had no previous cancer diagnosis during the period of 1958-1999. Dates of birth, BC diagnosis and TNM-stage where directly extracted from the cancer registry. The women's anti-diabetes therapy was gathered from the Swedish Prescribed Drug Registry. Information regarding the cause of death and date of death was obtained from the Cause of Death Registry and tbe Swedish Population Register up until the 31st of December 2012 and 31st of December 2013 respectively. Analyses have been restricted to patients receiving insulin therapy (n=2463) and their breast cancer prognosis has been calculated in comparison with breast cancer patients without diabetes. All analyses were adjusted for TNM-stage and age at diagnosis. Results. Patients with insulin treated diabetes had a worse prognosis compared with other women with breast cancer (HR 1.7, 95%CI 1.5-2.0). The worse prognosis could be seen both for patients with ER+ and ER- tumors. The worst prognosis was seen for patients treated with NPH insulins (HR 2.8, 95% CI 2.4-3.3) while patients treated with long-acting insulin analogs had an intermediate prognosis (HR 1.6, 95% CI 1.2-2.2). Those women treated with NPH insulins and metformin had a slightly worse prognosis (HR 1.4, 95% CI 1.0-1.8). The results for breast cancer specific survival and total survival were similar. Conclusion. Our results imply that insulin treated breast cancer patients have a worse survival compared with other women with breast cancer regardless of tumor stage. Metformin therapy may partially counteract the association.
|
|
| 42. |
|
|
| 43. |
|
|
| 44. |
|
|
| 45. |
|
|
| 46. |
- Högström, R., et al.
(författare)
-
DEVELOPMENT OF MEASUREMENT AND CALIBRATION TECHNIQUES FOR DYNAMIC PRESSURES AND TEMPERATURES : RESULTS AND ACHIEVEMENTS
- 2022
-
Ingår i: 6th TC16 Conference on Pressure and Vacuum Measurement 2022, Together with the 24th TC3 Conference on the Measurement of Force, Mass and Torque, the 14th TC5 Conference on the Measurement of Hardness, and the 5th TC22 Conference on Vibration Measurement. - : International Measurement Confederation (IMEKO).
-
Konferensbidrag (refereegranskat)abstract
- This paper presents the main results and achievements of the EMPIR DynPT project [1]. Dynamic measurement of pressure and temperature are a key requirement for process control in several demanding applications, such as automotive, marine and turbine engines, manufacturing processes, and ammunition and product safety. The quality of these measurement has been significantly improved in this project through development of dynamic measurement standards and methods and characterized sensor technologies and means of estimating measurement uncertainties in real process conditions.
|
|
| 47. |
- Kellen, Eliane, et al.
(författare)
-
Pooled analysis and meta-analysis of the glutathione S-transferase P1 lle 105Val polymorphism and bladder cancer: A HuGE-GSEC review
- 2007
-
Ingår i: American Journal of Epidemiology. - : Oxford University Press (OUP). - 0002-9262 .- 1476-6256. ; 165:11, s. 1221-1230
-
Forskningsöversikt (refereegranskat)abstract
- The glutathione S-transferase P1 genotype (GSTP1) is involved in the inactivation of cigarette smoke carcinogens, and sequence variation in the gene may alter bladder cancer susceptibility. To examine the association between GSTP1lle 105Val and bladder cancer, the authors undertook a meta- and pooled analysis. Summary crude and adjusted odds ratios and corresponding 95% confidence intervals were pooled by using a random-effects model. In the meta-analysis (16 studies, 4,273 cases and 5,081 controls), the unadjusted summary odds ratios for GSTP1 lle/Val and Val/Val compared with GSTP1 lle/lle were 1.54 (95% confidence interval: 1.21,1.99; p < 0.001) and 2.17 (95% confidence interval: 1.27, 3.71; p = 0.005). The association appeared to be the strongest in Asian countries. When the analysis was limited to European descendents (nine studies), the summary odds ratio decreased (odds ratio = 1.24, 95% confidence interval: 1.00, 1.52) (Q = 17.50; p = 0.02). All relevant data previously contributed to the International Study on Genetic Susceptibility to Environmental Carcinogens were pooled (eight studies, 1,305 cases and 1,558 controls). The summary odds ratios were similar to the ones from the meta-analysis. Case-only analyses did not detect an interaction between the GSTP1 genotype and smoking status (never/ever). GSTP1 lle 105Val appears to be associated with a modest increase in the risk of bladder cancer.
|
|
| 48. |
- Kjebon, Olle, et al.
(författare)
-
1.55 μm buried heterostructure laser via regrowth of semi-insulating InP:Fe around vertical mesas fabricated by reactive ion etching using methane and hydrogen
- 1991
-
Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 59:3, s. 235-255
-
Tidskriftsartikel (refereegranskat)abstract
- A GaInAsP/InP Fabry-Perot-type buried-heterostructure quantum well laser operating at 1.55 μm has been realized utilizing iron-doped semi-insulating InP around vertical mesas fabricated by reactive ion etching using methane and hydrogen. A maximum cw output power of 19 mW has been achieved on as-cleaved chips of 300 μm length with a quantum efficiency of 21% per facet. Threshold currents lie between 20 and 25 mA. As low as 2 Ω series resistance has been measured despite an ohmic contact area not exceeding that of the 2-μm-wide mesa. A 3 dB bandwidth of 7.5 GHz at 12 mW output power is obtained from the small-signal frequency modulation measurements.
|
|
| 49. |
|
|
| 50. |
|
|
